1. CV Risk reduction in T2DM with GLP-1 Agonists: Should We Change Our Clinical Practice?

3. Introduction/Background

4. What Is GLP-1?[a-c]

5. GLP-1: Multiple Direct Effects on Human Physiology[a,b]

6. GLP-1 RAs and Experimental Models of CVD

7. GLP-1 RAs and BP Reduction

8. GLP-1 RAs and Lipids Reduction

9. GLP-1 RA: Approved or in Development

10. SAVOR-TIMI, EXAMINE, TECOS: Topline Results[a-d]

11. Differences Between the 2 Classes of Incretin Agent

12. EMPA-REG: Primary Outcome (3-Point MACE) CV Death, Nonfatal MI, or Nonfatal Stroke

13. EMPA-REG: Results for CV Death

14. EMPA-REG Microvascular Outcomes: Renal Protection

15. LEADER: Primary Outcome*

16. LEADER: CV Death

17. LEADER: Time to First Renal Event -- Macroalbuminuria, Doubling of Serum Creatinine, ESRD, Renal Death

18. Potential Mechanisms for CV Benefit Associated With Empagliflozin

19. ELIXA (Lixisenatide): Primary Outcome CV Death, Nonfatal MI, Nonfatal Stroke, or Hospitalization for UA

20. SUSTAIN-6 (Semaglutide): Primary Outcome Results

21. Short-Acting GLP-1 RAs vs Long-Acting GLP-1 RAs

22. CDA Treatment Guidelines: 2016 Interim Update SGLT2 Inhibition

23. Conclusions

24. Abbreviations

25. Abbreviations (cont)